News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Eli Lilly and Company Hails Success of its New R&D Models
February 17, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Eli Lilly has been describing two innovative approaches to R&D that are bearing fruit, involving independent funding as well as its internal "lean virtual development organisation".
Twitter
LinkedIn
Facebook
Email
Print
Preclinical
Eli Lilly and Company
MORE ON THIS TOPIC
Cancer
ASH25: Late-Stage Data For J&J’s Tecvayli/Darzalex Combo Could ‘Shift Paradigm’ in Myeloma
November 25, 2025
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
November 24, 2025
·
1 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
November 24, 2025
·
3 min read
·
Heather McKenzie
Alzheimer’s disease
Novo’s GLP-1 Fails to Slow Alzheimer’s, Sending Shares Down 10%
November 24, 2025
·
2 min read
·
Annalee Armstrong
